Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PD-1 antibody plus low-dose apatinib for inoperable or metastatic pancreatic, biliary tract, or periampullary cancer
ChiCTR2000029187Phase 2Not yet recruiting
- Sponsor
- The Affiliated Hospital of Jiangnan University
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules, Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of camrelizumab and Rivoceranib in pancreatic cancer (PC), biliary cancer and Periampullary Carcinoma, sponsored by The Affiliated Hospital of Jiangnan University. Primary endpoints: Overall survival and Progression-free survival. Planned start Dec 2019; status: not yet recruiting.
02
Drugs
camrelizumabRivoceranib
03
Conditions
pancreatic cancer (PC)biliary cancerPeriampullary Carcinoma
Beyond the preview
Go deeper on ChiCTR2000029187.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000029187.